Carolina Villanueva1, Jenny Chang2, Scott M Bartell1,3, Argyrios Ziogas2, Robert Bristow4,5, Verónica M Vieira1,4. 1. Program in Public Health, Susan and Henry Samueli College of Health Sciences. 2. Department of Medicine, School of Medicine, and. 3. Department of Statistics, Donald Bren School of Information and Computer Sciences, University of California, Irvine, Irvine, California. 4. Chao Family Comprehensive Cancer Center, Orange, California; and. 5. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, School of Medicine, Orange, California.
Abstract
BACKGROUND: More than 14,000 women in the United States die of ovarian cancer (OC) every year. Disparities in survival have been observed by race and socioeconomic status (SES), and vary spatially even after adjusting for treatment received. This study aimed to determine the impact of geographic location on receiving treatment adherent to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for OC, independent of other predictors. PATIENTS AND METHODS: Women diagnosed with all stages of epithelial OC (1996-2014) were identified through the California Cancer Registry. Generalized additive models, smoothing for residential location, were used to calculate adjusted odds ratios (ORs) and 95% CIs for receiving nonadherent care throughout California. We assessed the impact of distance traveled for care, distance to closest high-quality hospital, race/ethnicity, and SES on receipt of quality care, adjusting for demographic and cancer characteristics and stratifying by disease stage. RESULTS: Of 29,844 patients with OC, 11,419 (38.3%) received guideline-adherent care. ORs for nonadherent care were lower in northern California and higher in Kern and Los Angeles counties. Magnitudes of associations with location varied by stage (OR range, 0.45-2.19). Living farther from a high-quality hospital increased the odds of receiving nonadherent care (OR, 1.18; 95% CI, 1.07-1.29), but travel >32 km to receive care was associated with decreased odds (OR, 0.76; 95% CI, 0.70-0.84). American Indian/other women were more likely to travel greater distances to receive care. Women in the highest SES quintile, those with Medicare insurance, and women of non-Hispanic black race were less likely to travel far. Patients who were Asian/Pacific Islander lived the closest to a high-quality hospital. CONCLUSIONS: Among California women diagnosed with OC, living closer to a high-quality center was associated with receiving adherent care. Non-Hispanic black women were less likely to receive adherent care, and women with lower SES lived farthest from high-quality hospitals. Geographic location in California is an independent predictor of adherence to NCCN Guidelines for OC.
BACKGROUND: More than 14,000 women in the United States die of ovarian cancer (OC) every year. Disparities in survival have been observed by race and socioeconomic status (SES), and vary spatially even after adjusting for treatment received. This study aimed to determine the impact of geographic location on receiving treatment adherent to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for OC, independent of other predictors. PATIENTS AND METHODS: Women diagnosed with all stages of epithelial OC (1996-2014) were identified through the California Cancer Registry. Generalized additive models, smoothing for residential location, were used to calculate adjusted odds ratios (ORs) and 95% CIs for receiving nonadherent care throughout California. We assessed the impact of distance traveled for care, distance to closest high-quality hospital, race/ethnicity, and SES on receipt of quality care, adjusting for demographic and cancer characteristics and stratifying by disease stage. RESULTS: Of 29,844 patients with OC, 11,419 (38.3%) received guideline-adherent care. ORs for nonadherent care were lower in northern California and higher in Kern and Los Angeles counties. Magnitudes of associations with location varied by stage (OR range, 0.45-2.19). Living farther from a high-quality hospital increased the odds of receiving nonadherent care (OR, 1.18; 95% CI, 1.07-1.29), but travel >32 km to receive care was associated with decreased odds (OR, 0.76; 95% CI, 0.70-0.84). American Indian/other women were more likely to travel greater distances to receive care. Women in the highest SES quintile, those with Medicare insurance, and women of non-Hispanic black race were less likely to travel far. Patients who were Asian/Pacific Islander lived the closest to a high-quality hospital. CONCLUSIONS: Among California women diagnosed with OC, living closer to a high-quality center was associated with receiving adherent care. Non-Hispanic black women were less likely to receive adherent care, and women with lower SES lived farthest from high-quality hospitals. Geographic location in California is an independent predictor of adherence to NCCN Guidelines for OC.
Authors: Robert E Bristow; Jenny Chang; Argyrios Ziogas; Daniel L Gillen; Lu Bai; Veronica M Vieira Journal: Am J Obstet Gynecol Date: 2015-01-31 Impact factor: 8.661
Authors: Kathleen M Fairfield; F Lee Lucas; Craig C Earle; Laurie Small; Edward L Trimble; Joan L Warren Journal: Cancer Date: 2010-10-15 Impact factor: 6.860
Authors: David A Barrington; Sarah E Dilley; Emily E Landers; Eric D Thomas; Jonathon D Boone; J Michael Straughn; Gerald McGwin; Charles A Leath Journal: Gynecol Oncol Date: 2016-10-06 Impact factor: 5.482
Authors: Britt K Erickson; Jovana Y Martin; Monjri M Shah; J Michael Straughn; Charles A Leath Journal: Gynecol Oncol Date: 2014-02-08 Impact factor: 5.482
Authors: David C Grossman; Susan J Curry; Douglas K Owens; Michael J Barry; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Alex H Krist; Ann E Kurth; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng Journal: JAMA Date: 2018-02-13 Impact factor: 56.272
Authors: Robert J Morgan; Ronald D Alvarez; Deborah K Armstrong; Robert A Burger; Mariana Castells; Lee-may Chen; Larry Copeland; Marta Ann Crispens; David Gershenson; Heidi Gray; Ardeshir Hakam; Laura J Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A Matulonis; David M O'Malley; Richard T Penson; Steven W Remmenga; Paul Sabbatini; Joseph T Santoso; Russell J Schilder; Julian Schink; Nelson Teng; Theresa L Werner; Miranda Hughes; Mary A Dwyer Journal: J Natl Compr Canc Netw Date: 2012-11-01 Impact factor: 11.908
Authors: Susan K Lutgendorf; Edgardo Ramirez; Andrew Schrepf; Mark C Valentine; Mary Charlton; M Bridget Zimmerman; Michael J Goodheart; Sharaf Zia; Anil K Sood; Premal H Thaker Journal: Gynecol Oncol Date: 2021-08-13 Impact factor: 5.304
Authors: Laura M Chambers; Meng Yao; Molly Morton; Morgan Gruner; Anna Chichura; Anthony B Costales; Max Horowitz; Peter G Rose; Chad M Michener; Robert Debernardo Journal: Gynecol Oncol Rep Date: 2022-02-28
Authors: Abigail S Zamorano; Angela L Mazul; Christine Marx; Mary M Mullen; Molly Greenwade; L Stewart Massad; Carolyn K McCourt; Andrea R Hagemann; Premal H Thaker; Katherine C Fuh; Matthew A Powell; David G Mutch; Dineo Khabele; Lindsay M Kuroki Journal: Gynecol Oncol Rep Date: 2022-10-03
Authors: Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer Journal: Cancer Date: 2021-08-04 Impact factor: 6.860